Alan Menter, M.D.

Dr. Alan Menter was born in England and received his dermatology residency training in South Africa. He subsequently undertook further postgraduate training and research at Guy's Hospital and St. John's Hospital for Diseases of the Skin in London, England. After moving to the United States, he completed a fellowship in Dermatology at Southwestern Medical School in Dallas. He was Board Certified in dermatology in 1977.

Dr Menter has written over 190 articles, 2 books, and 10 book chapters in peer reviewed medical publications, and has an international reputation as a clinician/researcher. In 2004, he spearheaded the formation of the International Psoriasis Council, for which he currently serves as President.

His recent international lectures include Brasilia, Buenos Aires, Copenhagen, Florence, Istanbul, London, Madrid, and Tokyo, as well as national lectures in Houston, Las Vegas, Los Angeles, New York City, Phoenix, San Antonio, and St. Louis. He has presented at various American Academy of Dermatology conferencesand at the World Congress of Dermatology in Buenos Aries in 2007.

President of the International Psoriasis Council

Chairman of the Division of Dermatology at Baylor University Medical Center Dallas

Clinical Professor of Dermatology at Southwestern Medical School Dallas

Director of Psoriasis Research, Baylor Research Institute

Member of the Board of Directors American Academy of Dermatology (1995-97)

President of the Texas Dermatology Society (1995-96)

Chairman of the Task Force on guidelines for Standards of Care for Psoriasis (1990-93)

Board Member and Texas State Chairman, Dermatology Foundation

Included in "Best Doctors in America" (1993-2005)

Dr. Menter, his wife Pam, and their three children moved to Dallas in 1975 and became U.S. citizens. An international rugby player, Dr. Menter brought to Texas not only his dermatologic skills, but his love of all sports and politics.

He holds membership in:

American Academy of Dermatology
American Dermatological Association
American Medical Association
American Osler Society
American Society for Laser Medicine & Surgery
American Society of Dermatologic Surgery
British Association of Dermatology
Dallas County Medical Society
Dallas Dermatological Society
Society for Investigative Dermatology
Texas Dermatological Society
Texas Medical Association

Some of the recent publications written by Dr. Alan Menter:

1. Helms C, Saccone NL, Cao L, Daw JA, Cao K, Hsu TM, Taillon-Miller P, Duan S, Gordon D, Pierce B, Ott J, Rice J, Fernandez-Vina MA, Kwok PY, Menter A, Bowcock A. Localization of PSORS1 to a haplotypes block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet 2005 Oct; 19:1-11.
2. Menter A, Cather JC, Baker D, Farber HF, Lebwohl M, Darif M. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006 Jan; 54(1):61-3.
3. Mease PJ, Menter MA. Quality of Life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies form a dermatology perspective. J Am Acad Dermatol 2006 Apr; 54(4):685-704.
4. Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC, Toth D. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006 Apr; 54(4 Suppl 1):S171-81. Review.
5. Menter A, Leonardi CL, Sterry W, Bos JD, Papp KA. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol 2006 Apr; 54(4 Suppl 1):S182-8. Review.
6. Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A, the Efalizumab Study Group. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial. Int J Dermatol. 2006 May; 45(5):605-614.
7. Li LY, Brimhall AK, Menter A. Systemic therapy for moderate-to-severe psoriasis. 2006 Expert Rev Dermatol; 1(1):77-92
8. Gordon KB, Langley RG, Leonardi D, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006 Oct; 55(4):598-606.
9. Lowe N, Horwitz S, Tanghetti E, Draelos Z, Menter A. Tazarotene versus tazarotene plus hydroquinone in the treatment of photodamaged facial skin: A multicenter, double-blind, randomized study. J Cosmet Laser Ther. 2006 Sep; 8(3):121-7.
10. Leonardi CL, Toth D, Cather JC, Langley RGB, Werther W, Compton P, Kwon P, Wetherill G, Curtin F, Menter A. Dermatology 2006; 213:204-214.
11. Menter A. Recent advances in psoriasis therapy and the work of the International Psoriasis Council. US Derm Review 2006; 1:23-27.
12. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007 Jan; 56(1):31.e1-e15.
13. Griffiths CEM, Christophers E, Barker JNWN, Chalmers RJG, Chimenti S, Krueger GG, Leonardi C, Menter AM, Ortonne JP, Fry L. A classification of psoriasis according to phenotype. Br J Dermatol 2007 Feb; 156:258-262.
14. Lebwohl M, Menter A, Weiss J, Clark SD, Flores J, Powers J, Balin AK, Kempers S, Glinett RJ, Fleming T, Liu Y, Graeber M, Pariser DM. Calcitriol 3mG/G ointment in the management of mild to moderate plaque type psoriasis: Results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2007; 6(4):428-35.

BOOKS:

Fast Facts – Psoriasis. 2002 Edition of Health Press Limited. Smith C, Barker J, and Menter A.
Fast Facts – Psoriasis. 2004 Edition of Science Press Limited. Menter A and Griffiths C